Abstract
Objective: To implement a lymphocyte immunotherapy program for women experiencing recurrent biochemical pregnancy loss and explore its clinical effects. Methods: The study employed a retrospective design. From January 2015 to January 2016, a total of 100 patients with recurrent biochemical pregnancy loss were enrolled as observation objects. Subsequently, the patients were divided into two groups based on different treatment plans, each comprising 50 cases. The observation group received conventional tocolysis in addition to lymphocyte immunotherapy, while the control group received only conventional tocolysis treatment. Evaluation criteria included pregnancy outcomes, improvements in serum factor levels, and treatment safety, enabling a comparison of the clinical effects of different treatment options. Results: In the observation group, the pregnancy success rate was 82.00%, whereas in the control group, it was 48.00% (χ2 = 12.7033, P < 0.05). Following treatment, levels of interferon-γ (IFN-γ) were higher in the observation group than in the control group, while levels of interleukin-8 (IL-8) and regulatory protein (BANTES) were lower in the observation group compared to the control group (P < 0.05). The difference in treatment safety between the two groups was negligible (P > 0.05). Conclusion: The incorporation of lymphocyte immunotherapy for patients with recurrent biochemical pregnancy loss can enhance successful pregnancy rates, demonstrating significant efficacy and warranting further application.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call